FY2026 Earnings Estimate for NVO Issued By Erste Group Bank

Key Points

• Erste Group Bank raised Novo Nordisk’s FY2026 EPS estimate to $3.46 from $3.27, slightly above the $3.45 consensus forecast, and projects FY2027 EPS of $3.34.
• Analyst sentiment remains mixed: Deutsche Bank downgraded the stock to Sell, while other firms maintained or upgraded their ratings. Overall, NVO has a consensus Hold rating and a $64.94 target price.
• Novo Nordisk shares opened at $45.59, near the lower end of their 52-week range, while the company reported $11.98 billion in quarterly revenue and $0.94 in EPS; institutional investors own 11.54% of the stock.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Equities research analysts at Erste Group Bank increased their FY2026 EPS estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.46 per share for the year, up from their previous estimate of $3.27. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.45 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S's FY2027 earnings at $3.34 EPS.

A number of other analysts have also issued reports on NVO. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating in a research report on Thursday. Nordea Equity Research upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $64.94.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $45.59 on Monday. The firm has a 50 day simple moving average of $48.03 and a 200-day simple moving average of $43.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market cap of $203.56 billion, a PE ratio of 11.15, a P/E/G ratio of 4.08 and a beta of 0.76. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion for the quarter.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NVO. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $25,000. Scarborough Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. Transamerica Financial Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 201.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company's stock worth $31,000 after purchasing an additional 403 shares during the period. Continuum Advisory LLC acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $38,000. Finally, Johnson Financial Group Inc. increased its position in Novo Nordisk A/S by 128.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company's stock worth $38,000 after purchasing an additional 384 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio is presently 20.05%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk's application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source